PMC9722440_01
Study design. BM, bone marrow; w, week; d, day; KTx, kidney transplant; SOC, standard of care treatment (including plasmapheresis 7x, intravenous immunoglobulins 100 mg/kg 7x, and corticosteroids); MSC, mesenchymal stem cell therapy; eGFR CKD EPI, estimated glomerular filtration rate according to the Chronic Kidney Disease Epidemiology Collaboration formula; ECC, excreted creatinine clearance; US, ultrasound; UPCR, urinary protein:creatinine ratio; HLA, human leukocyte antigen; DSA, donor specific antibodies; ATR1, antibodies against angiotensin receptor type 1; ETAR, antibodies against endothelin-1 type A receptor; miRNA, microRNA expression.
ti-35-10772-g001.jpg
PMC9722440_02_ti-35-10772-g001.jpg
F1
Expression of miRNA associated with AMR also showed no significant changes in expression profiles during the observation period (Supplementary Figure S1).
PMC9722440_02
Study design. BM, bone marrow; w, week; d, day; KTx, kidney transplant; SOC, standard of care treatment (including plasmapheresis 7x, intravenous immunoglobulins 100 mg/kg 7x, and corticosteroids); MSC, mesenchymal stem cell therapy; eGFR CKD EPI, estimated glomerular filtration rate according to the Chronic Kidney Disease Epidemiology Collaboration formula; ECC, excreted creatinine clearance; US, ultrasound; UPCR, urinary protein:creatinine ratio; HLA, human leukocyte antigen; DSA, donor specific antibodies; ATR1, antibodies against angiotensin receptor type 1; ETAR, antibodies against endothelin-1 type A receptor; miRNA, microRNA expression.
ti-35-10772-g001.jpg
PMC9722440_02_ti-35-10772-g001.jpg
F1
Expression of miRNA associated with AMR also showed no significant changes in expression profiles during the observation period (Supplementary Figure S1).
PMC9722440_03